Clinical trials: Coronary Stent Restenosis
Stent Restenosis, Coronary Artery Disease
Effect of Exercise Training in Coronary Artery Disease Patients After Stenting
To determine the effects of exercise training on ankle-brachial index and Quality of Life in coronary artery disease patients after stenting.
- Trial name
- NCT05315193
- Testing
- Structured In-patient and Home plan, Conventional Therapy
- Where
- Pakistan
- Volunteers
- 73 people
- Sponsor
- Riphah International University
In-stent Coronary Artery Restenosis
In-stent Restenosis in Patients With Patent Previous Bare Metal Stent
Intra-coronary stents deployment reduces the rate of angiographic restenosis as compared to Balloon angioplasty. in-stent restenosis, usually defined as ≥50 percent diameter stenosis within previously deployed stent, is most…
- Trial name
- NCT01296399
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Rambam Health Care Campus
Coronary Restenosis
Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)
The PACCOCATH ISR II study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in coronary in-stent restenosis.
- Trial name
- NCT00409981
- Testing
- paclitaxel coated balloon catheter (device with drug)
- Where
- 5 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital, Saarland
Myocardial Ischemia, Coronary Artery Stenosis
ABSORB EXTEND Clinical Investigation
The ABSORB EXTEND trial is to continue the assessment of the safety and performance of the ABSORB Bioresorbable Vascular Scaffold (BVS) System ABSORB BVS is currently in development at Abbott Vascular.
- Conditions
- Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
- Trial name
- ABSORB EXTEND (NCT01023789)
- Testing
- ABSORB BVS
- Where
- 56 sites in Argentina, Australia and 23 more
- Volunteers
- 812 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Coronary Restenosis
Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR
AbsorbISR is a randomized, controlled trial, single center, prospective, not blinded to evaluate two strategies of in stent restenosis treatment: Implantation of drug eluting bioresorbable stent scaffold Absorb® vs.
- Trial name
- AbsorbISR (NCT02474485)
- Testing
- BVS Absorb implantation., DEB Sequent Please inflation., Control coronary angiography.
- Where
- Switzerland
- Volunteers
- 53 people
- Sponsor
- SIS Medical AG
Coronary Atherosclerosis, Coronary Restenosis
PIoglitazone for PrEvention of Restenosis in Diabetic Patients
Restenosis requiring reintervention is still a limitation of percutaneous coronary angioplasty. Despite the use of Drug eluting stent (DES), the rate of restenosis remains 7% to 16% in diabetic patients, making it a challenging…
- Conditions
- Coronary Atherosclerosis, Coronary Restenosis, Diabetes
- Trial name
- NCT00376870
- Testing
- Pioglitazone
- Where
- 2 sites in Italy
- Volunteers
- 160 people
- Sponsor
- University of Rome Tor Vergata
Coronary Artery Disease, Ischemic Heart Disease
Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis
The possibility of using the new drug eluting stents (DES) technology has significantly changed the mid-term outcome of percutaneous coronary interventions (PCI) in terms of reduced recurrence of angina.
- Conditions
- Coronary Artery Disease, Ischemic Heart Disease, Atherosclerosis
- Trial name
- NCT00369356
- Testing
- Prednisone, Drug eluting coronary stent, Bare metal coronary stent
- Where
- 5 sites in Italy
- Volunteers
- 375 people
- Sponsor
- Universita di Verona
Arteriosclerosis of Arterial Coronary Artery Bypass Graft
Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions
The aim of this study is to compare the efficacy of drug-eluting stents and bare metal stents to reduce reblockage of bypass grafts after coronary stenting
- Trial name
- ISAR-CABG (NCT00611910)
- Testing
- sirolimus-eluting stent, paclitaxel-eluting stent, biodegradable-polymer-based sirolimus-eluting stent
- Where
- 4 sites in Germany
- Volunteers
- 610 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
The Safety and Efficacy of Biolimus in the Treatment of Patients With in Stent Restenosis
This study consisted of a randomized controlled trial group and a long balloon observation group. In the randomized control group, 280 subjects with in-stent restenosis were planned to be recruited and randomly assigned to the…
- Trial name
- NCT04733443
- Testing
- Biolimus, SeQuent® Please Neo
- Where
- China
- Volunteers
- 310 people
- Sponsor
- JW Medical Systems Ltd
Coronary Restenosis
EGO-COMBO Clinical End-point Extension Study Beyond 36 Months
In this study, the safety and efficacy of COMBO TM stent beyond 36 months are assessed, in particular the occurrence of late stent thrombosis and late loss catch-up (restenosis).
- Trial name
- NCT02263313
- Testing
- EGO-COMBO group
- Where
- China
- Volunteers
- 59 people
- Sponsor
- The University of Hong Kong
In-Stent Restenosis
P E P C A D II, The Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease to Treat In-Stent Restenoses
The aim of the study is to assess the safety and efficacy of the Paclitaxel-eluting PTCA-balloon in the treatment of in-stent restenoses in native coronary arteries with reference diameters between 2.5 mm and 3.5 mm and ≤ 22 mm…
- Trial name
- NCT00393315
- Testing
- paclitaxel coated balloon catheter
- Where
- 10 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University Hospital, Saarland
Coronary Artery Disease, Arterial Occlusive Diseases
The ENDEAVOR II Clinical Trial: The Medtronic Endeavor Drug Eluting Coronary Stent System in Coronary Artery Lesions
To demonstrate the safety and efficacy of the Driver Coronary Stent coated with 10 mcg/mm ABT-578 compared to the uncoated Driver Stent for the treatment of single de novo lesions in native coronary arteries 2.25-3.5 mm in…
- Conditions
- Coronary Artery Disease, Arterial Occlusive Diseases, Coronary Disease, Coronary Arteriosclerosis
- Trial name
- ENDEAVOR II (NCT00614848)
- Testing
- Endeavor drug eluting coronary stent
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Medtronic Vascular
Coronary Disease
Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis
The purpose of the study is to evaluate the effectively of coating of coronary stents with two different doses of rapamycin for the prevention of coronary vessel re-blockage
- Trial name
- NCT00152308
- Testing
- 2% rapamycin-eluting YUKONdes PEARL-stent, 1% rapamycin-eluting YUKONdes PEARL-stent
- Where
- 10 sites in Austria, Germany and 1 more
- Volunteers
- 333 people
- Sponsor
- Translumina GmbH
Coronary Vessels
Debulking With Rotational Atherectomy Versus Balloon Angioplasty In Patients With In-stent Restenosis
This study is to establish the primary hypothesis that debulking with rotational atherectomy (RA) followed by balloon angioplasty (BA) is superior to BA alone for lesion preparation in patients with coronary in-stent restenosis…
- Trial name
- ROTA-ISR (NCT03401203)
- Testing
- Rotational atherectomy followed by balloon angioplasty, Balloon angioplasty
- Where
- 3 sites in South Korea
- Volunteers
- 95 people
- Sponsor
- Seung-Jung Park
In-stent Restenosis
Diffuse Type In-Stent Restenosis After Drug-Eluting Stent
To evaluate the best therapeutic option for the treatment of diffuse type post-drug-eluting stent restenosis.
- Trial name
- DES-ISR (NCT00485030)
- Testing
- Cypher, Xience-V
- Where
- 15 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- Seung-Jung Park
Restenosis, Coronary, Left Main Coronary Artery Disease
PCI vs. CABG in UPLM-ISR
Left main (LM) coronary artery disease is associated with high morbidity and mortality owing to the large myocardial territory at risk for ischemia.
- Conditions
- Restenosis, Coronary, Left Main Coronary Artery Disease, PTCA Left Main Artery Complications
- Trial name
- LM-DRAGON (NCT04968977)
- Testing
- PCI vs. CABG
- Where
- 11 sites in Italy, Poland
- Volunteers
- 305 people
- Sponsor
- Medical University of Silesia
Coronary Artery Stenosis, Coronary Arteriosclerosis
XIENCE V: SPIRIT WOMEN
The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME™ EECSS) with the primary focus on clinical outcomes in the treatment of female…
- Conditions
- Coronary Artery Stenosis, Coronary Arteriosclerosis, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT00496938
- Testing
- XIENCE V®/ XIENCE PRIME™
- Where
- 95 sites in Argentina, Australia and 24 more
- Volunteers
- 1,600 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Restenosis of Coronary Artery Stent
Oral Colchicine in Argentina to Prevent Restenosis
The Oral treatment of Colchicine in Argentina (ORCA) trial is a prospective, randomized, multicenter trial to included 450 patients with indication for myocardial revascularization with PCI between a group to be treated with BMS…
- Conditions
- Coronary Artery Disease, Restenosis of Coronary Artery Stent, Atherosclerosis, Acute Coronary Syndrome
- Trial name
- ORCA (NCT04382443)
- Testing
- Colchicine
- Where
- 2 sites in Argentina
- Volunteers
- 410 people
- Sponsor
- Centro de estudios en Cardiologia Intervencionista
Coronary Angioplasty, Restenosis
Optimal Strategy to Correct Stent underexpAnsion in Resistant Lesions
Percutaneous coronary intervention (PCI) for in-stent restenosis (ISR) accounts for 5-10% of PCI. ISR may be linked to mechanical complications mainly under-expansion (UE), neointimal hyperplasia and/or neoatherosclerosis.
- Conditions
- Coronary Angioplasty, Restenosis, Lithotripsy, Restenosis of Coronary Artery Stent
- Trial name
- OSCAR (NCT07316504)
- Testing
- Intravascular lithotripsy, Balloon
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Clermont-Ferrand
Coronary Restenosis
Oral Sirolimus for In-Stent Restenosis
Despite recent advances in interventional cardiology including the success of drug-eluting stents in de-novo coronary lesions, the treatment of in-stent restenosis remains a challenging clinical issue.
- Trial name
- OSIRIS (NCT00859183)
- Testing
- Sirolimus
- Where
- 3 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Deutsches Herzzentrum Muenchen